Mitsubishi Chemical Medience Corporation Patent applications |
Patent application number | Title | Published |
20140212894 | METHOD OF DIAGNOSING SURGICAL SITE INFECTIONS - A marker useful in diagnosing surgical site infections is provided. In the method of the present invention for detecting surgical site infections, sCD14-ST in a sample is measured. | 07-31-2014 |
20140199711 | METHOD FOR DETERMINING GLUCAGON-LIKE PEPTIDE-1, AND KIT FOR USE IN SAID METHOD - Provided is a method of measuring the presence and/or the amount of glucagon-like peptide-1 (GLP-1) in a sample, which method is characterized by comprising the step of treating the sample in advance with an acidic solution, and a kit of measuring the presence and/or an amount of GLP-1 in a sample, the kit containing (a) the acidic solution, (b) an antibody specific to GLP-1, and (c) an instruction manual. | 07-17-2014 |
20140193842 | NON-SPECIFIC REACTION INHIBITOR, METHOD FOR INHIBITING NON-SPECIFIC REACTION, AND KIT - Provided is a non-specific reaction inhibitor for achieving the accurate detection and quantitation of a trace component (a target substance) contained in a sample, in an immunoassay, by simply and effectively inhibiting a non-specific reaction associated with the measurement. | 07-10-2014 |
20140017712 | IMMUNOLOGICAL MEASURING METHOD AND MEASURING KIT FOR WHOLE BLOOD SAMPLE - In a known method of measuring a target substance, comprising: providing a sample solution containing the target substance, a first reaction solution, and a second reaction solution; sequentially aspirating the sample solution and the first reaction solution, using a measuring apparatus equipped with a dispensing unit, into the dispensing unit; discharging them at a time from the dispensing unit, to bring them into contact with the second reaction solution, and to form a complex of the target substance and a first partner which is contained in at least one of the first reaction solution or the second reaction solution and reacts specifically with the target substance; and analyzing the resulting complex, an improved method capable of inhibiting a reaction which adversely affects measurement results is provided. In this improved method, the specific gravity of the sample solution is different from the specific gravity of the first reaction solution; and the sample solution and the first reaction solution are aspirated into the dispensing unit in an overlaid state. | 01-16-2014 |
20130330841 | METHOD FOR MEASURING CARDIAC TROPONIN - Disclosed are a method for immunologically measuring cardiac troponin in a biological sample, in which the formation of an immunological complex of cardiac troponin with an antibody specifically binding thereto is performed in the presence of a divalent cation at 4 mmol/L or more; and a kit for measuring cardiac troponin, comprising an antibody specifically binding to cardiac troponin, and a buffer containing a divalent cation at a high concentration. According to the method or the kit, a stable and highly-accurate measured value can be obtained without being affected by interfering substances in a specimen regardless of the type of specimen. | 12-12-2013 |
20130288276 | METHOD FOR PREDICTION OF PROGNOSIS OF SEPSIS - Disclosed is a prediction method for the prognosis of sepsis comprising measuring an sCD14-ST level in a sample. sCD14-ST, to be measured in the present invention, is a marker superior to procalcitonin, known as a marker to predict the prognosis in sepsis patients. | 10-31-2013 |
20130230881 | METHOD AND APPARATUS FOR TESTING CARDIOTOXICITY AND EVALUATING CARDIOMYOCYTES - In the present invention, a cardiomyocyte cluster is disposed on a transparent substrate, and the quality of the cardiomyocytes is evaluated from the response of the cells to a forced pulsation stimulus applied to the cardiomyocytes. The cardiomyocyte cluster is disposed on the transparent substrate, and is exposed to the flow of a liquid containing an agent in a manner so that the agent acts on the cells, which configure a network. The extent of cardiac toxicity resulting from the agent is evaluated from measuring the fluctuations obtained from a comparison of adjacent cardiomyocytes of the network. | 09-05-2013 |
20130177918 | INHIBITION METHOD OF NUCLEIC ACID AMPLIFICATION BY PHOTOIRRADIATION AND METHOD OF SELECTIVE NUCLEIC ACID AMPLIFICATION WITH HIGH SENSITIVITY - Provided is a method for rapidly and easily detecting a mutated nucleic acid, which is contained in a small amount in a nucleic acid sample together with wild-type nucleic acids, with high specificity and high sensitivity. In the method of the present invention, amplification of a detection region comprising a target site by a nucleic acid amplification method is inhibited, by the steps of allowing a nucleic acid having a target site to coexist with a clamp probe comprising a photo-crosslinking nucleic acid and having a sequence complementary to the target site, and photo-crosslinking the nucleic acid having the target site with the clamp probe by photo-irradiation. | 07-11-2013 |
20130085081 | RISK PREDICTION OF DEVELOPING DRUG-INDUCED LUNG INJURY AND DETECTION METHOD AND KIT OF GENE FOR RISK PREDICTION - Disclosed are a method of detecting the presence or absence of a single nucleotide polymorphism of a gene, for prediction of the risk of developing drug-induced lung injury, or for improving a therapeutic method, and a kit for carrying out the detection method. The detection method is characterized by comparing an ABCB1 gene in a biological sample with a wild-type ABCB1 gene to detect the presence or absence of a single nucleotide polymorphism in the ABCB1 gene in the biological sample, in particular, by determining the nucleotide at position 3751 of the CDS of the ABCB1 gene. The kit comprises an oligonucleotide probe which specifically binds to a single nucleotide polymorphism in an ABCB1 gene under selective binding conditions, or an oligonucleotide primer which amplifies a nucleic acid sequence comprising a single nucleotide polymorphism in an ABCB1 gene. | 04-04-2013 |
20130022985 | EXAMINATION METHOD TO DETERMINE CONTRACTION OR ACTIVITY OF DISEASES RELATED IMMUNE SYSTEM OR JOINT SYSTEM - The present invention provides an examination method for determining the contraction or the activity of diseases related to immune system and/or joint system, comprising measuring the expression level of miRNA in a blood-derived or joint-derived fluid sample. The present invention is an examination method for determining the activity of diseases related to immune system and/or joint system, comprising: preparing blood-derived fluid samples collected over time, measuring the expression levels of at least an miRNA selected from SEQ ID NOS: 1 to 5 in the fluid samples, and comparing the expression levels between different sampling times. | 01-24-2013 |
20130011869 | NOVEL MONOCLONAL ANTIBODIES AND METHOD OF IMMUNOLOGICAL ANALYSIS OF D-DIMER - Provided are an antibody capable of specifically and accurately measuring digested products of stabilized fibrin (D-dimer), and a method and a reagent for measuring D-dimer using the antibody. The antibody specifically reacts with D-dimer, which is plasmin-digested products of stabilized fibrin, but does not react with fibrinogen or plasmin-digested products of fibrinogen, which include fragment X, fragment Y, fragment D1, and fragment E3, and does not react with dissociation products of DD/E monomer, which include fragment DD, fragment E1, and fragment E2. | 01-10-2013 |
20130005589 | HIGHLY SENSITIVE METHOD FOR DETECTING MUTATED GENE - Various highly sensitive detection methods, particularly improved PNA-LNA-PCR clamp methods, are provided as methods for detecting the presence or absence of a mutated gene contained in a gene pool rapidly, in a simple manner, with high accuracy, and with high sensitivity. As a step before the main step for detection, a pre-amplification step comprising allowing (1) a clamp primer consisting of PNA which hybridizes with all or part of a target site having a sequence of a wild-type gene or a sequence complementary to the wild-type gene, (2) a primer capable of amplifying a region comprising a target site having a sequence of the mutated gene, and (3) the gene pool to coexist in a reaction solution for gene amplification, and selectively amplifying the region comprising a target site of the mutated gene by a gene amplification method. | 01-03-2013 |
20120244544 | METHOD FOR DETECTING MICROORGANISMS BELONGING TO MYCOPLASMA PNEUMONIAE AND/OR MYCOPLASMA GENITALIUM - A detection method and a detection kit for rapidly and specifically diagnosing | 09-27-2012 |
20120142043 | METHOD FOR AUTOMATIC DETERMINATION OF SAMPLE - A method of determining a kind of a sample, in a method for analyzing a substance by the steps of supplying the sample to be analyzed to a reaction system by a supplying means comprising a transparent region composed of a transparent material, reacting a reagent for detecting the substance with the sample in the reaction system, and analyzing a signal derived from a product obtained by the reaction, characterized by irradiating the transparent region with light in the supplying step, and analyzing an optical intensity of the light. | 06-07-2012 |
20110262958 | DEVICE FOR EXAMINING MYOCARDIAL TOXICITY, CHIP FOR EXAMINING MYOCARDIAL TOXICITY AND METHOD FOR EXAMINING MYOCARDIAL TOXICITY - [Problem] To provide a device and a method for examining myocardial toxicity, which can be realized in vitro in an equivalent manner as those conventionally carried out in vivo. | 10-27-2011 |
20110189704 | NON-SPECIFIC REACTION INHIBITOR - Disclosed is a non-specific reaction inhibitor for use in an immunological measurement, comprising a complex of an antibody or a fragment of the antibody capable of specifically binding to a non-specific reaction factor, and a polymer. The non-specific reaction inhibitor can inhibit a non-specific reaction which may interfere with the accurate detection or quantification of a trace substance in an immunological measurement method. | 08-04-2011 |
20110143369 | METHOD FOR DETERMINING TREATMENT OF DISSEMINATED INTRAVASCULAR COAGULATION - A method for determining an appropriate treatment option for a patient who has been diagnosed with disseminated intravascular coagulation (DIC) but who may have thrombotic thrombocytopenic purpura (TTP), by analyzing the amount and/or enzyme activity of a von Willebrand factor (vWF)-cleaving protease (ADAMTS13) and the amount of vWF in a patient that has been diagnosed with DIC is disclosed. Using the method of the present invention, a differential diagnosis of patients with thrombotic thrombocytopenic purpura (TTP) can be made from among patients diagnosed with DIC, which could not previously be distinguished on the basis of only clinical findings or known markers. Also disclosed is a kit for determining an appropriate treatment option, the kit comprising an antibody or a fragment thereof which specifically binds to ADAMTS13. | 06-16-2011 |
20110039721 | METHOD FOR PREDICTION ABOUT CARCINOGENICITY OF SUBSTANCE IN RODENT - Disclosed is a method for predicting about the carcinogenicity of a substance of interest in a rodent, which comprises the steps of: administering a solution of the substance to a test group and administering a solvent used in the solution to a control group; extracting mRNA from each of the test group and the control group, and measuring the expression level of mRNA for each of genes obtained by selecting at least one gene from (A) genes each comprising a nucleotide sequence depicted in any one of SEQ ID NOs: 1 to 5, (B) genes each comprising a nucleotide sequence depicted in any one of SEQ ID NOs: 6 to 8 and (C) genes each comprising a nucleotide sequence depicted in any one of SEQ ID NOs: 9 to 32; determining whether or not a significant difference in the level of mRNA expressed from the gene is observed between the test group and the control group; and determining that the substance has carcinogenicity when a significant difference in the level of the expression of mRNA from any one of the genes is observed between the test group and the control group and the direction of increase or decrease in the level of the expression of mRNA from any one of the genes is the same as the tendency which is previously defined for each gene. | 02-17-2011 |
20110014633 | ELECTRIC ANALYSIS METHOD - Disclosed is an analysis method comprising the steps of: | 01-20-2011 |
20100178692 | MODEL CELL CHIP, APPARATUS FOR EVALUATING DRUG EFFECT USING THE MODEL CELL CHIP AND METHOD OF EVALUATING DRUG EFFECT - The present invention provides an apparatus for evaluating a drug effect enabling on-chip evaluation of the effect of a drug while the drug is acting on hERG-expressing cells. The present invention also provides a myocardial toxicity test apparatus and method therefor enabling in vitro myocardial toxicity testing that has previously been performed in vivo. | 07-15-2010 |
20100173351 | CARDIAC REENTRY MODEL CHIP AND APPARATUS AND METHOD FOR EVALUATING DRUG USING THE CARDIAC REENTRY MODEL CHIP - A chip has been developed that can accurately measure cell potential and cell morphology on a single cell basis. The chip also constitutes a cardiac model that comprises a closed loop whereupon cardiomyocytes and fibroblasts are suitably dispersed and arranged, and that can evaluate the effects of a drug thereon. An in vitro cardiac reentry model chip is fabricated by constructing a closed loop comprising cardiomyocytes and fibroblasts arrayed on transparent electrodes formed on a transparent substrate by using a constitution where single cells are enclosed in a specific spatial configuration. A pulse wave of a random cardiomyocyte or a specific cardiomyocyte is propagated on both sides of the loop, and the pulsation status of the cells in the loop is detected electrically. A drug is applied to this cardiac reentry model chip, and the benefit or toxicity of the drug to cardiomyocytes is evaluated by measuring the cell potentials of individual cells. | 07-08-2010 |